Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Cristal Therapeutics.

    Client Virtual Booth

    CRISTAL THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Cristal Therapeutics
    Netherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Oxfordlaan 55 6229 EV Maastricht
    Telephone
    Telephone
    +31 433 88 58 68
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cristaltherapeutics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering

    Details:

    The collaborations will enable the integration of McSAF Inside® and Cristal Therapeutic's CliCr®, into the Lonza Bioconjugation Toolbox and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug conjugate.


    Lead Product(s): Antibody-drug Conjugate

    Therapeutic Area: Technology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Recipient: Lonza Group

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration January 17, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

    Details:

    Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac® vaccine candidate based on the receptor-binding domain of the SARS-CoV-2 spike protein.


    Lead Product(s): COVID-19 Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Intravacc

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration January 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search